Associated Genetic Biomarkers
Liver neoplasms most frequently harbor alterations in TP53, CTNNB1, ARID1A, IDH1, and BAP1 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, CTNNB1 Mutation, and IDH1 Mutation are the most common alterations in liver neoplasm .
There is 1 clinical trial for liver neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains liver neoplasm as an inclusion criterion, 1 is phase 1/phase 2 (1 open).
HLA-A*02 is the most frequent gene inclusion criterion for liver neoplasm clinical trials .
Et140203 is the most common intervention in liver neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.